Overview
Molecular diagnostic firm's Adjusted EPS for Q4 beat analyst expectations
Company reaffirmed financial guidance for full-year 2026
Outlook
Myriad Genetics reaffirms full-year 2026 revenue guidance of $860 mln to $880 mln
Result Drivers
TEST VOLUME GROWTH - Prolaris prostate cancer test volume grew 12%, Hereditary cancer testing grew 9%, and GeneSight grew 9% year-over-year, attributed to strengthened execution across the commercial team
HEADWINDS IMPACT - Revenue growth was affected by the discontinuation of GeneSight coverage by UnitedHealthcare and the divestiture of the European EndoPredict business
Company press release: ID:nGNX3TLhKp
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Adjusted EPS | Beat | $0.04 | -$0.01 (13 Analysts) |
Q4 EPS | -$0.08 | ||
Q4 Net Income | -$7.90 mln | ||
Q4 Gross Margin | 70.00% | ||
Q4 Adjusted Operating Expenses | $139 mln | ||
Q4 Operating Expenses | $152.50 mln | ||
Q4 Operating Income | -$5.70 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 7 "hold" and 3 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Myriad Genetics Inc is $7.00, about 63.2% above its February 20 closing price of $4.29
The stock recently traded at 78 times the next 12-month earnings vs. a P/E of 93 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)